Fuller & Thaler Asset Management, Inc. Alkermes Plc. Transaction History

Fuller & Thaler Asset Management, Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$26.4 - $32.56 $4.71 Million - $5.81 Million	178,332 Added 39.52%	629,593 $17 Million
Q4 2023 Feb 13, 2024	BUY	$23.37 - $28.68 $898,319 - $1.1 Million	38,439 Added 9.31%	451,261 $12.5 Million
Q3 2023 Nov 13, 2023	BUY	$27.17 - $31.97 $899,028 - $1.06 Million	33,089 Added 8.71%	412,822 $11.6 Million
Q2 2023 Aug 14, 2023	BUY	$28.34 - $33.63 $1.11 Million - $1.32 Million	39,199 Added 11.51%	379,733 $11.9 Million
Q1 2023 May 15, 2023	BUY	$25.31 - $29.02 $620,297 - $711,222	24,508 Added 7.76%	340,534 $9.6 Million
Q4 2022 Feb 13, 2023	SELL	$21.94 - $26.24 $154,742 - $185,070	-7,053 Reduced 2.18%	316,026 $8.26 Million
Q3 2022 Nov 14, 2022	BUY	$22.0 - $31.87 $193,952 - $280,965	8,816 Added 2.81%	323,079 $7.21 Million
Q2 2022 Aug 12, 2022	BUY	$26.4 - $30.54 $8.3 Million - $9.6 Million	314,263 New	314,263 $9.36 Million
Q1 2021 May 13, 2021	SELL	$18.21 - $23.2 $9.63 Million - $12.3 Million	-528,972 Closed	0 $0
Q4 2020 Feb 11, 2021	BUY	$15.39 - $22.1 $8.14 Million - $11.7 Million	528,972 New	528,972 $10.6 Million

362

181M

175K

96.6K

Ticker ALKS
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 164,254,000
Market Cap $5.14B
Description
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...

Get notified when there are updates to the investment portfolio of Fuller & Thaler Asset Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Fuller & Thaler Asset Management, Inc. with notifications on news.